Proinflammatory characteristics of SMAC/DIABLO-induced cell death in antitumor therapy

Cancer Research

Volumn 72, Issue 6, 2012, Pages 1342-1352

  Emeagi, Perpetua U ^a   Van Lint, Sandra ^a   Goyvaerts, Cleo ^a   Maenhout, Sarah ^a   Cauwels, Anje ^b   McNeish, Iain A ^c   Bos, Tomas ^a   Heirman, Carlo ^a   Thielemans, Kris ^a   Aerts, Joeri L ^a   Breckpot, Karine ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALRETICULIN; GAMMA INTERFERON; HIGH MOBILITY GROUP B1 PROTEIN; LENTIVIRUS VECTOR; PROGRAMMED DEATH 1 RECEPTOR; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL DEATH; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; IN VITRO STUDY; INFLAMMATION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SURVIVAL; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; BIOMIMETIC MATERIALS; CALRETICULIN; CD8-POSITIVE T-LYMPHOCYTES; CELL DEATH; CELL LINE, TUMOR; DENDRITIC CELLS; FEMALE; HUMANS; INFLAMMATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LENTIVIRUS; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, INBRED DBA; MITOCHONDRIAL PROTEINS; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; TRANSDUCTION, GENETIC;

EID: 84858163320     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-2400     Document Type: Article

References (45)

1. Vucic D, Fairbrother WJ. The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin Cancer Res 2007;13:5995-6000. (Pubitemid 350075054)
2. Grossman D, McNiff JM, Li F, Altieri DC. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 1999;113:1076-81. (Pubitemid 30013356)
3. Vucic D, Stennicke HR, Pisabarro MT, Salvesen GS, Dixit VM. ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr Biol 2000;10:1359-66.
4. Ruttinger D, Li R, Poehlein CH, Haley D, Walker EB, Hu HM, et al. Increased susceptibility to immune destruction of B16BL6 tumor cells engineered to express a novel pro-Smac fusion protein. J Immunother 2008;31:43-51. (Pubitemid 351619403)
5. Martinez-Ruiz G, Maldonado V, Ceballos-Cancino G, Grajeda JP, Melendez-Zajgla J. Role of Smac/DIABLO in cancer progression. J Exp Clin Cancer Res 2008;27:48.
6. Arnt CR, Chiorean MV, Heldebrant MP, Gores GJ, Kaufmann SH. Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J Biol Chem 2002;277:44236-43. (Pubitemid 36157856)
7. Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X, Harran PG. A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science 2004;305:1471-4. (Pubitemid 39167668)
8. Bockbrader KM, Tan M, Sun Y. A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells. Oncogene 2005;24:7381-8. (Pubitemid 41622242)
9. Vince JE, Wong WW,Khan N, Feltham R, Chau D, Ahmed AU, et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007;131:682-93. (Pubitemid 350103599)
10. McNeish IA, Bell S, McKay T, Tenev T, Marani M, Lemoine NR. Expression of Smac/DIABLO in ovarian carcinoma cells induces apoptosis via a caspase-9-mediated pathway. Exp Cell Res 2003;286:186-98. (Pubitemid 36566432)
11. Li R, Ruttinger D, Urba W, Fox BA, Hu HM. Targeting and amplification of immune killing of tumor cells by pro-Smac. Int J Cancer 2004;109:85-94. (Pubitemid 38160666)
12. McNeish IA, Lopes R, Bell SJ, McKay TR, Fernandez M, Lockley M, et al. Survivin interacts with Smac/DIABLO in ovarian carcinoma cells but is redundant in Smac-mediated apoptosis. Exp Cell Res 2005;302:69-82. (Pubitemid 39485236)
13. Fricke I, Gabrilovich DI. Dendritic cells and tumor microenvironment: a dangerous liaison. Immunol Invest 2006;35:459-83. (Pubitemid 44266783)
14. Zitvogel L, Kepp O, Kroemer G. Decoding cell death signals in inflammation and immunity. Cell 2010;140:798-804.
15. Feijoo E, Alfaro C, Mazzolini G, Serra P, Penuelas I, Arina A, et al. Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8. Int J Cancer 2005;116:275-81. (Pubitemid 40967265)
16. Weber A, Kirejczyk Z, Besch R, Potthoff S, Leverkus M, Hacker G. Proapoptotic signalling through Toll-like receptor-3 involves TRIF-dependent activation of caspase-8 and is under the control of inhibitor of apoptosis proteins in melanoma cells. Cell Death Differ 2010;17:942-51.
17. Breckpot K, Emeagi P, Dullaers M, Michiels A, Heirman C, Thielemans K. Activation of immature monocyte-derived dendritic cells after transduction with high doses of lentiviral vectors. Hum Gene Ther 2007;18:536-46. (Pubitemid 47036047)
18. Breckpot K, Escors D, Arce F, Lopes L, Karwacz K, Van Lint S, et al. HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7. J Virol 2010;84:5627-36.
19. Zeissig S, Dougan SK, Barral DC, Junker Y, Chen Z, Kaser A, et al. Primary deficiency ofmicrosomal triglyceride transfer protein in human abetalipoproteinemia is associated with loss of CD1 function. J Clin Invest 2010;120:2889-99.
20. Nettelbeck DM, Jerome V, Muller R. A dual specificity promoter system combining cell cycle-regulated and tissue-specific transcriptional control. Gene Ther 1999;6:1276-81. (Pubitemid 29359021)
21. Baird SK, Aerts JL, Eddaoudi A, Lockley M, Lemoine NR, McNeish IA. Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer. Oncogene 2008;27:3081-90. (Pubitemid 351693172)
22. Breckpot K, Dullaers M, Bonehill A, van Meirvenne S, Heirman C, de Greef C, et al. Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. J Gene Med 2003;5:654-67. (Pubitemid 40309704)
23. Aerts-Toegaert C, Heirman C, Tuyaerts S, Corthals J, Aerts JL, Bonehill A, et al. CD83 expression on dendritic cells and T cells: correlation with effective immune responses. Eur J Immunol 2007;37:686-95. (Pubitemid 46916935)
24. Keyaerts M, Verschueren J, Bos TJ, Tchouate-Gainkam LO, Peleman C, Breckpot K, et al. Dynamic bioluminescence imaging for quantitative tumour burden assessment using IV or IP administration of D: -luciferin: effect on intensity, time kinetics and repeatability of photon emission. Eur J Nucl Med Mol Imaging 2008;35:999-1007.
25. Dullaers M, Van Meirvenne S, Heirman C, Straetman L, Bonehill A, Aerts JL, et al. Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors. Gene Ther 2006;13:630-40.
26. Tuyaerts S, Noppe SM, Corthals J, Breckpot K, Heirman C, De Greef C, et al. Generation of large numbers of dendritic cells in a closed system using Cell Factories. J Immunol Methods 2002;264:135-51. (Pubitemid 34615899)
27. Yu J, Wang P, Ming L, Wood MA, Zhang L. SMAC/Diablo mediates the proapoptotic function of PUMA by regulating PUMA-induced mitochondrial events. Oncogene 2007;26:4189-98. (Pubitemid 46975795)
28. Friboulet L, Gourzones C, Tsao SW, Morel Y, Paturel C, Temam S, et al. Poly(I:C) induces intense expression of c-IAP2 and cooperates with an IAP inhibitor in induction of apoptosis in cancer cells. BMC Cancer 2010;10:327.
29. Petrigliano FA, Virk MS, Liu N, Sugiyama O, Yu D, Lieberman JR. Targeting of prostate cancer cells by a cytotoxic lentiviral vector containing a prostate stem cell antigen (PSCA) promoter. Prostate 2009;69:1422-34.
30. Gerolami R, Uch R, Faivre J, Garcia S, Hardwigsen J, Cardoso J, et al. Herpes simplex virus thymidine kinase-mediated suicide gene therapy for hepatocellular carcinoma using HIV-1-derived lentiviral vectors. J Hepatol 2004;40:291-7. (Pubitemid 38115835)
31. Wherry EJ. T cell exhaustion. Nat Immunol 2011;131:492-9.
32. Zhou Q, Xiao H, Liu Y, Peng Y, Hong Y, Yagita H, et al. Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization. J Immunol 2010;185:5082-92.
33. Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+T cell dysfunction in melanoma patients. J Exp Med 2010;207:2175-86.
34. Jarnicki AG, Lysaght J, Todryk S, Mills KH. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol 2006;177:896-904. (Pubitemid 44036590)
35. Larmonier N, Marron M, Zeng Y, Cantrell J, Romanoski A, Sepassi M, et al. Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. Cancer Immunol Immunother 2007;56:48-59. (Pubitemid 44812446)
36. Arce F, Breckpot K, Stephenson H, Karwacz K, Ehrenstein MR, Collins M, et al. Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigen-specific regulatory T cells, and suppresses experimental inflammatory arthritis. Arthritis Rheum 2011;63:84-95.
37. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-13. (Pubitemid 36077915)
38. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9. (Pubitemid 39273735)
39. Bonnotte B, Favre N, Moutet M, Fromentin A, Solary E, Martin M, et al. Role of tumor cell apoptosis in tumor antigen migration to the draining lymph nodes. J Immunol 2000;164:1995-2000. (Pubitemid 30108755)
40. Gardai SJ, McPhillips KA, Frasch SC, Janssen WJ, Starefeldt A, Murphy-Ullrich JE, et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 2005;123:321-34. (Pubitemid 41457220)
41. Kepp O, Galluzzi L, Martins I, Schlemmer F, Adjemian S, Michaud M, et al. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev 2011;30:61-9.
42. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007;13:1050-9. (Pubitemid 47517504)
43. Escors D, Breckpot K. Lentiviral vectors in gene therapy: their current status and future potential. Arch Immunol Ther Exp (Warsz) 2010;58:107-19.
44. Goyvaerts C, De Groeve K, Dingemans J, Van Lint S, Robays L, et al. Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells. Gene Ther. 2012 Jan 12. [Epub ahead of print].
45. Breckpot K, Aerts JL, Thielemans K. Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics. Gene Ther 2007;14:847-62. (Pubitemid 46780068)